These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7950850)

  • 21. Evaluating managed mental health programs.
    Whitted GS; Kunnes R
    AAPPO J; 1993; 3(2):27-30. PubMed ID: 10171662
    [No Abstract]   [Full Text] [Related]  

  • 22. A critical review of accounting and economic methods for estimating the costs of addiction treatment.
    Cartwright WS
    J Subst Abuse Treat; 2008 Apr; 34(3):302-10. PubMed ID: 17614244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug addict rehabilitation: a burden on society?
    Berg JE; Andersen S
    Int J Rehabil Res; 1992; 15(4):301-9. PubMed ID: 1336768
    [No Abstract]   [Full Text] [Related]  

  • 24. Benefit-cost in the California treatment outcome project: does substance abuse treatment "pay for itself"?
    Ettner SL; Huang D; Evans E; Ash DR; Hardy M; Jourabchi M; Hser YI
    Health Serv Res; 2006 Feb; 41(1):192-213. PubMed ID: 16430607
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benefit-cost analysis of residential and outpatient addiction treatment in the State of Washington.
    French MT; Salomé HJ; Krupski A; McKay JR; Donovan DM; McLellan AT; Durell J
    Eval Rev; 2000 Dec; 24(6):609-34. PubMed ID: 11151519
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI.
    French MT; Salomé HJ; Sindelar JL; McLellan AT
    Health Serv Res; 2002 Apr; 37(2):433-55. PubMed ID: 12036002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving cost-effectiveness in a substance abuse treatment program.
    Francis E; Hughes P; Schinka J
    Psychiatr Serv; 1999 May; 50(5):633-5. PubMed ID: 10332897
    [No Abstract]   [Full Text] [Related]  

  • 28. The outcome and cost of alcohol and drug treatment in an HMO: day hospital versus traditional outpatient regimens.
    Weisner C; Mertens J; Parthasarathy S; Moore C; Hunkeler EM; Hu T; Selby JV
    Health Serv Res; 2000 Oct; 35(4):791-812. PubMed ID: 11055449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using the DATCAP and ASI to estimate the costs and benefits of residential addiction treatment in the State of Washington.
    French MT; Salomé HJ; Carney M
    Soc Sci Med; 2002 Dec; 55(12):2267-82. PubMed ID: 12409139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Costing substance misuse services.
    Coyle D; Godfrey C; Hardman G; Raistrick D
    Addiction; 1997 Aug; 92(8):1007-15. PubMed ID: 9376770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An organisational change intervention for increasing the delivery of smoking cessation support in addiction treatment centres: study protocol for a randomized controlled trial.
    Bonevski B; Guillaumier A; Shakeshaft A; Farrell M; Tzelepis F; Walsberger S; D'Este C; Paul C; Dunlop A; Searles A; Kelly P; Fry R; Stirling R; Fowlie C; Skelton E
    Trials; 2016 Jun; 17(1):290. PubMed ID: 27301489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utilization and costs of substance abuse services within The HMO Group.
    Levin BL
    HMO Pract; 1993 Mar; 7(1):28-34. PubMed ID: 10171407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug misuse services. No quick fixes.
    Thomson R; Bellis M
    Health Serv J; 1997 Oct; 107(5576):30-1. PubMed ID: 10174936
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Despite Resources From The ACA, Most States Do Little To Help Addiction Treatment Programs Implement Health Care Reform.
    Andrews C; Abraham A; Grogan CM; Pollack HA; Bersamira C; Humphreys K; Friedmann P
    Health Aff (Millwood); 2015 May; 34(5):828-35. PubMed ID: 25941285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychotropic drug use and expenditures among medicaid beneficiaries with and without other mental health or substance abuse services.
    Hennessy KD; Green-Hennessy S; Buck JA; Miller K
    J Nerv Ment Dis; 2003 Jul; 191(7):476-8. PubMed ID: 12891096
    [No Abstract]   [Full Text] [Related]  

  • 37. The effect of reforms on spending for veterans' substance abuse treatment, 1993-1999.
    Chen S; Wagner TH; Barnett PG
    Health Aff (Millwood); 2001; 20(4):169-75. PubMed ID: 11463073
    [No Abstract]   [Full Text] [Related]  

  • 38. Day treatment versus enhanced standard methadone services for opioid-dependent patients: a comparison of clinical efficacy and cost.
    Avants SK; Margolin A; Sindelar JL; Rounsaville BJ; Schottenfeld R; Stine S; Cooney NL; Rosenheck RA; Li SH; Kosten TR
    Am J Psychiatry; 1999 Jan; 156(1):27-33. PubMed ID: 9892294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Financing of substance abuse treatment for children and adolescents. Committee on Child Health Financing and Committee on Substance Abuse, American Academy of Pediatrics.
    Pediatrics; 1995 Feb; 95(2):308-10. PubMed ID: 7838656
    [No Abstract]   [Full Text] [Related]  

  • 40. The San Francisco centralized intake unit: a description of participants and service episodes.
    Woods WJ; Klingemann SD; Guydish JR
    J Psychoactive Drugs; 2002; 34(1):17-24. PubMed ID: 12003109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.